Ignite Creation Date:
2025-12-24 @ 6:40 PM
Ignite Modification Date:
2026-01-29 @ 12:04 PM
Study NCT ID:
NCT00674557
Status:
TERMINATED
Last Update Posted:
2013-07-10
First Post:
2008-05-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
Sponsor:
Cancer Research UK
Organization:
Study Overview
Official Title:
A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer
Status:
TERMINATED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Withdrawn as the clinical development of ATN-224 was terminated by the drug company who was providing ATN-224 for the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow to the tumor. It is not yet known whether giving exemestane together with ATN-224 is more effective than giving exemestane alone in treating patients with recurrent or advanced breast cancer.
PURPOSE: This randomized phase II trial is studying the side effects of exemestane given together with or without ATN-224 and to see how well it works in treating postmenopausal women with recurrent or advanced breast cancer.
PURPOSE: This randomized phase II trial is studying the side effects of exemestane given together with or without ATN-224 and to see how well it works in treating postmenopausal women with recurrent or advanced breast cancer.
Detailed Description:
OBJECTIVES:
Primary
* Compare progression-free survival of postmenopausal women with, estrogen receptor- and/or progesterone receptor-positive recurrent or advanced breast cancer treated with exemestane with versus without SOD1 inhibitor ATN-224.
* Establish the safety of SOD1 inhibitor ATN-224 in combination with exemestane in these patients.
Secondary
* Determine the response rate (overall, at 16 and 24 weeks), response duration, and rate of stable disease for ≥ 16 and ≥ 24 weeks in these patients.
* Determine the clinical benefit rate (complete response, partial response, and stable disease) at 16 and 24 weeks in these patients.
* Investigate the time course of suppression of serum ceruloplasmin (Cp, surrogate for copper).
* Investigate serum estradiol and estrone sulphate levels in these patients to assess if SOD1 inhibitor ATN-224 interacts with the aromatase inhibition of exemestane.
Tertiary
* Investigate the pharmacokinetic behavior of SOD1 inhibitor ATN-224 in combination with exemestane.
* Investigate superoxide dismutase 1 (SOD1) activity in red blood cells and cytokine levels in plasma samples from these patients.
* Investigate circulating endothelial cell levels, circulating endothelial RNA levels, and proteome profiles in blood samples at baseline and during treatment, from these patients.
* Investigate SOD1, lysyl oxidase and copper-dependent proteins expression, and endothelial growth factor receptor-related cell-signaling pathways in historical tumor samples from all patients entered on the study.
OUTLINE: This is a multicenter study. Patients are stratified according to prior aromatase inhibitor therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive oral exemestane and oral SOD1 inhibitor ATN-224 once daily.
* Arm II: Patients receive oral exemestane once daily. In both arms, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
Blood samples are collected periodically for pharmacokinetic and pharmacodynamic assessments, including Cp levels, estradiol and estrone sulfate, SOD1 levels, cytokines, proteomics, circulating endothelial RNA, circulating endothelial cells, protein expression, and EGFR-related cell signaling pathways.
After completion of study treatment patients are followed at 28 days.
Primary
* Compare progression-free survival of postmenopausal women with, estrogen receptor- and/or progesterone receptor-positive recurrent or advanced breast cancer treated with exemestane with versus without SOD1 inhibitor ATN-224.
* Establish the safety of SOD1 inhibitor ATN-224 in combination with exemestane in these patients.
Secondary
* Determine the response rate (overall, at 16 and 24 weeks), response duration, and rate of stable disease for ≥ 16 and ≥ 24 weeks in these patients.
* Determine the clinical benefit rate (complete response, partial response, and stable disease) at 16 and 24 weeks in these patients.
* Investigate the time course of suppression of serum ceruloplasmin (Cp, surrogate for copper).
* Investigate serum estradiol and estrone sulphate levels in these patients to assess if SOD1 inhibitor ATN-224 interacts with the aromatase inhibition of exemestane.
Tertiary
* Investigate the pharmacokinetic behavior of SOD1 inhibitor ATN-224 in combination with exemestane.
* Investigate superoxide dismutase 1 (SOD1) activity in red blood cells and cytokine levels in plasma samples from these patients.
* Investigate circulating endothelial cell levels, circulating endothelial RNA levels, and proteome profiles in blood samples at baseline and during treatment, from these patients.
* Investigate SOD1, lysyl oxidase and copper-dependent proteins expression, and endothelial growth factor receptor-related cell-signaling pathways in historical tumor samples from all patients entered on the study.
OUTLINE: This is a multicenter study. Patients are stratified according to prior aromatase inhibitor therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive oral exemestane and oral SOD1 inhibitor ATN-224 once daily.
* Arm II: Patients receive oral exemestane once daily. In both arms, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
Blood samples are collected periodically for pharmacokinetic and pharmacodynamic assessments, including Cp levels, estradiol and estrone sulfate, SOD1 levels, cytokines, proteomics, circulating endothelial RNA, circulating endothelial cells, protein expression, and EGFR-related cell signaling pathways.
After completion of study treatment patients are followed at 28 days.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: